|
Fusion gene ID: 17179 |
FusionGeneSummary for IGF2_YY1 |
Fusion gene summary |
Fusion gene information | Fusion gene name: IGF2_YY1 | Fusion gene ID: 17179 | Hgene | Tgene | Gene symbol | IGF2 | YY1 | Gene ID | 3481 | 7528 |
Gene name | insulin like growth factor 2 | YY1 transcription factor | |
Synonyms | C11orf43|GRDF|IGF-II|PP9974 | DELTA|GADEVS|INO80S|NF-E1|UCRBP|YIN-YANG-1 | |
Cytomap | 11p15.5 | 14q32.2 | |
Type of gene | protein-coding | protein-coding | |
Description | insulin-like growth factor IIT3M-11-derived growth factorinsulin-like growth factor 2 (somatomedin A)insulin-like growth factor type 2preptin | transcriptional repressor protein YY1INO80 complex subunit SYY-1Yin and Yang 1 proteindelta transcription factor | |
Modification date | 20180527 | 20180527 | |
UniProtAcc | P01344 | P25490 | |
Ensembl transtripts involved in fusion gene | ENST00000381395, ENST00000381406, ENST00000416167, ENST00000300632, ENST00000434045, ENST00000381392, ENST00000381389, ENST00000418738, | ENST00000262238, | |
Fusion gene scores | * DoF score | 10 X 5 X 8=400 | 6 X 4 X 5=120 |
# samples | 12 | 7 | |
** MAII score | log2(12/400*10)=-1.73696559416621 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/120*10)=-0.777607578663552 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: IGF2 [Title/Abstract] AND YY1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | IGF2 | GO:0008284 | positive regulation of cell proliferation | 28873464 |
Hgene | IGF2 | GO:0042104 | positive regulation of activated T cell proliferation | 15694994 |
Hgene | IGF2 | GO:0043410 | positive regulation of MAPK cascade | 11500939 |
Hgene | IGF2 | GO:0045840 | positive regulation of mitotic nuclear division | 11500939 |
Hgene | IGF2 | GO:0046628 | positive regulation of insulin receptor signaling pathway | 11500939 |
Hgene | IGF2 | GO:0051897 | positive regulation of protein kinase B signaling | 11500939 |
Tgene | YY1 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 9857059|16260628 |
Tgene | YY1 | GO:0032688 | negative regulation of interferon-beta production | 16260628 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | RV | UCS | TCGA-N5-A4RO-01A | IGF2 | chr11 | 2150351 | - | YY1 | chr14 | 100728641 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
intron-3CDS | ENST00000381395 | ENST00000262238 | IGF2 | chr11 | 2150351 | - | YY1 | chr14 | 100728641 | + |
intron-3CDS | ENST00000381406 | ENST00000262238 | IGF2 | chr11 | 2150351 | - | YY1 | chr14 | 100728641 | + |
intron-3CDS | ENST00000416167 | ENST00000262238 | IGF2 | chr11 | 2150351 | - | YY1 | chr14 | 100728641 | + |
In-frame | ENST00000300632 | ENST00000262238 | IGF2 | chr11 | 2150351 | - | YY1 | chr14 | 100728641 | + |
intron-3CDS | ENST00000434045 | ENST00000262238 | IGF2 | chr11 | 2150351 | - | YY1 | chr14 | 100728641 | + |
intron-3CDS | ENST00000381392 | ENST00000262238 | IGF2 | chr11 | 2150351 | - | YY1 | chr14 | 100728641 | + |
intron-3CDS | ENST00000381389 | ENST00000262238 | IGF2 | chr11 | 2150351 | - | YY1 | chr14 | 100728641 | + |
intron-3CDS | ENST00000418738 | ENST00000262238 | IGF2 | chr11 | 2150351 | - | YY1 | chr14 | 100728641 | + |
Top |
FusionProtFeatures for IGF2_YY1 |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
IGF2 | YY1 |
Multifunctional transcription factor that exhibitspositive and negative control on a large number of cellular andviral genes by binding to sites overlapping the transcriptionstart site. Binds to the consensus sequence 5'-CCGCCATNTT-3'; somegenes have been shown to contain a longer binding motif allowingenhanced binding; the initial CG dinucleotide can be methylatedgreatly reducing the binding affinity. The effect on transcriptionregulation is depending upon the context in which it binds anddiverse mechanisms of action include direct activation orrepression, indirect activation or repression via cofactorrecruitment, or activation or repression by disruption of bindingsites or conformational DNA changes. Its activity is regulated bytranscription factors and cytoplasmic proteins that have beenshown to abrogate or completely inhibit YY1-mediated activation orrepression. For example, it acts as a repressor in absence ofadenovirus E1A protein but as an activator in its presence. Actssynergistically with the SMAD1 and SMAD4 in bone morphogeneticprotein (BMP)-mediated cardiac-specific gene expression(PubMed:15329343). Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiacactivating regions. May play an important role in development anddifferentiation. Proposed to recruit the PRC2/EED-EZH2 complex totarget genes that are transcriptional repressed. Involved in DNArepair. In vitro, binds to DNA recombination intermediatestructures (Holliday junctions). Plays a role in regulatingenhancer activation (PubMed:28575647).{ECO:0000269|PubMed:15329343, ECO:0000269|PubMed:24326773,ECO:0000269|PubMed:25787250, ECO:0000269|PubMed:28575647}. Proposed core component of the chromatin remodelingINO80 complex which is involved in transcriptional regulation, DNAreplication and probably DNA repair; proposed to target the INO80complex to YY1-responsive elements. {ECO:0000269|PubMed:17721549,ECO:0000269|PubMed:18026119}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for IGF2_YY1 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
>In-frame_IGF2_ENST00000300632_chr11_2150351_-_YY1_ENST00000262238_chr14_100728641_+_188aa MKKKILTMRQWLKNRSLERTHLLIIQNIXQERNFLLEEYLALTSQIPNNWQNLLEXSQEKLKKMMLQEQXLALIKAAQRCSGITRPXENI CTPTVPESTSVQNVAKLLLRVQNXNDTNWFILERSPFSARSKAVGNAFHWTSICAHMCESIPETGPMCAPSMVVIRSLLSQLTXNLTSXH |
* Fusion transcript sequences (only coding sequence (CDS) region). |
>In-frame_IGF2_ENST00000300632_chr11_2150351_-_YY1_ENST00000262238_chr14_100728641_+_566nt ATGAAAAAAAAGATATTGACCATGAGACAGTGGTTGAAGAACAGATCATTGGAGAGAACTCACCTCCTGATTATTCAGAATATATGACAG GAAAGAAACTTCCTCCTGGAGGAATACCTGGCATTGACCTCTCAGATCCCAAACAACTGGCAGAATTTGCTAGAATGAAGCCAAGAAAAA TTAAAGAAGATGATGCTCCAAGAACAATAGCTTGCCCTCATAAAGGCTGCACAAAGATGTTCAGGGATAACTCGGCCATGAGAAAACATC TGCACACCCACGGTCCCAGAGTCCACGTCTGTGCAGAATGTGGCAAAGCTTTTGTTGAGAGTTCAAAACTAAAACGACACCAACTGGTTC ATACTGGAGAGAAGCCCTTTCAGTGCACGTTCGAAGGCTGTGGGAAACGCTTTTCACTGGACTTCAATTTGCGCACACATGTGCGAATCC ATACCGGAGACAGGCCCTATGTGTGCCCCTTCGATGGTTGTAATAAGAAGTTTGCTCAGTCAACTAACCTGAAATCTCACATCTTAACAC |
* Fusion transcript sequences (Full-length transcript). |
>In-frame_IGF2_ENST00000300632_chr11_2150351_-_YY1_ENST00000262238_chr14_100728641_+_10896nt CCGCTAATGTACCATGCCCTGGTGCTGGAAAGTGCCTGAGCCAGCTGCCCCAGCGGCCTCAGCACTACCAAGTTGGCACAAAGCTCCCCA AATTCGGAGGGGCTCAGGGAAACGAGTGGAGGGGATGAGGAGGTGAGGGGTAAACCCATCATTTCAGTTGGCATTTGAGCAGGTGCCATG CTCAGCGGAGATGAGGCTCTCCCATCTGTAGGGGCCGTATTAACATGCACACTCTAAAAGTGCCCTTCGTTTCTCCAGCCTCAGCTTTGT CCCTCTCCTCCTCCACGTCAACCTGGCCAGAGGGTCTGGACGCCACAGCCAGGGCACCCCCTGCTTTGGTGGTGACTGCTAATATTGGCC AGGCCGGCGGATCATCGTCCAGGCAGTTTCGGCAGAGAGCCTTGGGCACCAGTGACTCCCCGGTCCTCTTTATCCACTGTCCAGGAGCTG CGGGGACTGCGCAGGGACTAGAGTACAGGGGCCGAAGAGTCACCACCGAGCTTGTGTGGGAGGAGGTGGATTCCAGCCCCCAGCCCCAGG GCTCTGAATCGCTGCCAGCTCAGCCCCCTGCCCAGCCTGCCCCACAGCCTGAGCCCCAGCAGGCCAGAGAGCCCAGTCCTGAGGTGAGCT GCTGTGGCCTGTGGCCCAGGCGACCCCAGCGCTCCCAGAACTGAGGCTGGCAGCCAGCCCCAGCCTCAGCCCCAACTGCGAGGCAGAGAG ACACCAATGGGAATCCCAATGGGGAAGTCGATGCTGGTGCTTCTCACCTTCTTGGCCTTCGCCTCGTGCTGCATTGCTGCTTACCGCCCC AGTGAGACCCTGTGCGGCGGGGAGCTGGTGGACACCCTCCAGTTCGTCTGTGGGGACCGCGGCTTCTACTTCAGCAGGCCCGCAAGCCGT GTGAGCCGTCGCAGCCGTGGCATCGTTGAGGAGTGCTGTTTCCGCAGCTGTGACCTGGCCCTCCTGGAGACGTACTGTGCTACCCCCGCC AAGTCCGAGAGGGACGTGTCGACCCCTCCGACCGTGCTTCCGGACAACTTCCCCAGATACCCCGTGGGCAAGTTCTTCCAATATGACACC TGGAAGCAGTCCACCCAGCGCCTGCGCAGGGGCCTGCCTGCCCTCCTGCGTGCCCGCCGGGGTCACGTGCTCGCCAAGGAGCTCGAGGCG TTCAGGGAGGCCAAACGTCACCGTCCCCTGATTGCTCTACCCACCCAAGACCCCGCCCACGGGGGCGCCCCCCCAGAGATGGCCAGCAAT CGGAAGTGAGCAAAACTGCCGCAAGTCTGCAGCCCGGCGCCACCATCCTGCAGCCTCCTCCTGACCACGGACGTTTCCATCAGGTTCCAT CCCGAAAATCTCTCGGTTCCACGTCCCCCTGGGGCTTCTCCTGACCCAGTCCCCGTGCCCCGCCTCCCCGAAACAGGCTACTCTCCTCGG CCCCCTCCATCGGGCTGAGGAAGCACAGCAGCATCTTCAAACATGTACAAAATCGATTGGCTTTAAACACCCTTCACATACCCTCCCCCC AAATTATCCCCAATTATCCCCACACATAAAAAATCAAAACATTAAACTAACCCCCTTCCCCCCCCCCCACAACAACCCTCTTAAAACTAA TTGGCTTTTTAGAAACACCCCACAAAAGCTCAGAAATTGGCTTTAAAAAAAACAACCACCAAAAAAAATCAATTGGCTAAAAAAAAAAAG TATTAAAAACGAATTGGCTGAGAAACAATTGGCAAAATAAAGGAATTTGGCACTCCCCACCCCCCTCTTTCTCTTCTCCCTTGGACTTTG AGTCAAATTGGCCTGGACTTGAGTCCCTGAACCAGCAAAGAGAAAAGAAGGACCCCAGAAATCACAGGTGGGCACGTCGCTGCTACCGCC ATCTCCCTTCTCACGGGAATTTTCAGGGTAAACTGGCCATCCGAAAATAGCAACAACCCAGACTGGCTCCTCACTCCCTTTTCCATCACT AAAAATCACAGAGCAGTCAGAGGGACCCAGTAAGACCAAAGGAGGGGAGGACAGAGCATGAAAACCAAAATCCATGCAAATGAAATGTAA TTGGCACGACCCTCACCCCCAAATCTTACATCTCAATTCCCATCCTAAAAAGCACTCATACTTTATGCATCCCCGCAGCTACACACACAC AACACACAGCACACGCATGAACACAGCACACACACGAGCACAGCACACACACAAACGCACAGCACACACAGCACACAGATGAGCACACAG CACACACACAAACGCACAGCACACACACGCACACACATGCACACACAGCACACAAACGCACGGCACACACACGCACACACATGCACACAC AGCACACACACAAACGCACAGCACACACAAACGCACAGCACACACGCACACACAGCACACACACGAGCACACAGCACACAAACGCACAGC ACACGCACACACATGCACACACAGCACACACACTAGCACACAGCACACACACAAAGACACAGCACACACATGCACACACAGCACACACAC GCGAACACAGCACACACGAACACAGCACACACAGCACACACACAAACACAGCACACACATGCACACAGCACACGCACACACAGCACACAC ATGAACACAGCACACAGCACACACATGCACACACAGCACACACGCATGCACAGCACACATGAACACAGCACACACACAAACACACAGCAC ACACATGCACACACAGCACACACACTCATGCGCAGCACATACATGAACACAGCTCACAGCACACAAACACGCAGCACACACGTTGCACAC GCAAGCACCCACCTGCACACACACATGCGCACACACACGCACACCCCCACAAAATTGGATGAAAACAATAAGCATATCTAAGCAACTACG ATATCTGTATGGATCAGGCCAAAGTCCCGCTAAGATTCTCCAATGTTTTCATGGTCTGAGCCCCGCTCCTGTTCCCATCTCCACTGCCCC TCGGCCCTGTCTGTGCCCTGCCTCTCAGAGGAGGGGGCTCAGATGGTGCGGCCTGAGTGTGCGGCCGGCGGCATTTGGGATACACCCGTA GGGTGGGCGGGGTGTGTCCCAGGCCTAATTCCATCTTTCCACCATGACAGAGATGCCCTTGTGAGGCTGGCCTCCTTGGCGCCTGTCCCC ACGGCCCCCGCAGCGTGAGCCACGATGCTCCCCATACCCCACCCATTCCCGATACACCTTACTTACTGTGTGTTGGCCCAGCCAGAGTGA GGAAGGAGTTTGGCCACATTGGAGATGGCGGTAGCTGAGCAGACATGCCCCCACGAGTAGCCTGACTCCCTGGTGTGCTCCTGGAAGGAA GATCTTGGGGACCCCCCCACCGGAGCACACCTAGGGATCATCTTTGCCCGTCTCCTGGGGACCCCCCAAGAAATGTGGAGTCCTCGGGGG CCGTGCACTGATGCGGGGAGTGTGGGAAGTCTGGCGGTTGGAGGGGTGGGTGGGGGGCAGTGGGGGCTGGGCGGGGGGAGTTCTGGGGTA GGAAGTGGTCCCGGGAGATTTTGGATGGAAAAGTCAGGAGGATTGACAGCAGACTTGCAGAATTACATAGAGAAATTAGGAACCCCCAAA TTTCATGTCAATTGATCTATTCCCCCTCTTTGTTTCTTGGGGCATTTTTCCTTTTTTTTTTTTTTTTGTTTTTTTTTTACCCCTCCTTAG CTTTATGCGCTCAGAAACCAAATTAAACCCCCCCCCCATGTAACAGGGGGGCAGTGACAAAAGCAAGAACGCACGAAGCCAGCCTGGAGA CCACCACGTCCTGCCCCCCGCCATTTATCGCCCTGATTGGATTTTGTTTTTCATCTGTCCCTGTTGCTTGGGTTGAGTTGAGGGTGGAGC CTCCTGGGGGGCACTGGCCACTGAGCCCCCTTGGAGAAGTCAGAGGGGAGTGGAGAAGGCCACTGTCCGGCCTGGCTTCTGGGGACAGTG GCTGGTCCCCAGAAGTCCTGAGGGCGGAGGGGGGGGTTGGGCAGGGTCTCCTCAGGTGTCAGGAGGGTGCTCGGAGGCCACAGGAGGGGG CTCCTGGCTGGCCTGAGGCTGGCCGGAGGGGAAGGGGCTAGCAGGTGTGTAAACAGAGGGTTCCATCAGGCTGGGGCAGGGTGGCCGCCT TCCGCACACTTGAGGAACCCTCCCCTCTCCCTCGGTGACATCTTGCCCGCCCCTCAGCACCCTGCCTTGTCTCCAGGAGGTCCGAAGCTC TGTGGGACCTCTTGGGGGCAAGGTGGGGTGAGGCCGGGGAGTAGGGAGGTCAGGCGGGTCTGAGCCCACAGAGCAGGAGAGCTGCCAGGT CTGCCCATCGACCAGGTTGCTTGGGCCCCGGAGCCCACGGGTCTGGTGATGCCATAGCAGCCACCACCGCGGCGCCTAGGGCTGCGGCAG GGACTCGGCCTCTGGGAGGTTTACCTCGCCCCCACTTGTGCCCCCAGCTCAGCCCCCCTGCACGCAGCCCGACTAGCAGTCTAGAGGCCT GAGGCTTCTGGGTCCTGGTGACGGGGCTGGCATGACCCCGGGGGTCGTCCATGCCAGTCCGCCTCAGTCGCAGAGGGTCCCTCGGCAAGC GCCCTGTGAGTGGGCCATTCGGAACATTGGACAGAAGCCCAAAGAGCCAAATTGTCACAATTGTGGAACCCACATTGGCCTGAGATCCAA AACGCTTCGAGGCACCCCAAATTACCTGCCCATTCGTCAGGACACCCACCCACCCAGTGTTATATTCTGCCTCGCCGGAGTGGGTGTTCC CGGGGGCACTTGCCGACCAGCCCCTTGCGTCCCCAGGTTTGCAGCTCTCCCCTGGGCCACTAACCATCCTGGCCCGGGCTGCCTGTCTGA CCTCCGTGCCTAGTCGTGGCTCTCCATCTTGTCTCCTCCCCGTGTCCCCAATGTCTTCAGTGGGGGGCCCCCTCTTGGGTCCCCTCCTCT GCCATCACCTGAAGACCCCCACGCCAAACACTGAATGTCACCTGTGCCTGCCGCCTCGGTCCACCTTGCGGCCCGTGTTTGACTCAACTC AACTCCTTTAACGCTAATATTTCCGGCAAAATCCCATGCTTGGGTTTTGTCTTTAACCTTGTAACGCTTGCAATCCCAATAAAGCATTAA AAGTCATGATGAAAAAAAAGATATTGACCATGAGACAGTGGTTGAAGAACAGATCATTGGAGAGAACTCACCTCCTGATTATTCAGAATA TATGACAGGAAAGAAACTTCCTCCTGGAGGAATACCTGGCATTGACCTCTCAGATCCCAAACAACTGGCAGAATTTGCTAGAATGAAGCC AAGAAAAATTAAAGAAGATGATGCTCCAAGAACAATAGCTTGCCCTCATAAAGGCTGCACAAAGATGTTCAGGGATAACTCGGCCATGAG AAAACATCTGCACACCCACGGTCCCAGAGTCCACGTCTGTGCAGAATGTGGCAAAGCTTTTGTTGAGAGTTCAAAACTAAAACGACACCA ACTGGTTCATACTGGAGAGAAGCCCTTTCAGTGCACGTTCGAAGGCTGTGGGAAACGCTTTTCACTGGACTTCAATTTGCGCACACATGT GCGAATCCATACCGGAGACAGGCCCTATGTGTGCCCCTTCGATGGTTGTAATAAGAAGTTTGCTCAGTCAACTAACCTGAAATCTCACAT CTTAACACATGCTAAGGCCAAAAACAACCAGTGAAAAGAAGAGAGAAGACCCTTCTCGACCACGGGAAGCATCTTCCAGAAGTGTGATTG GGAATAAATATGCCTCTCCTTTGTATATTATTTCTAGGAAGAATTTTAAAAATGAATCCTACACACCTAAGGGACATGTTTTGATAAAGT AGTAAAAATTAAAAAAAAAAAACTTTACTAAGATGACATTGCTAAGATGCTCTATCTTGCTCTGTAATCTCGTTTCAAAAACACAGTGTT TTTGTAAAGTGTGGTCCCAACAGGAGGACAATTCATGAACTTCGCATCAAAAGACAATTCTTTATACAACAGTGCTAAAAATGGGACTTC TTTTCACATTCTTATAAATATGAAGCTCACCTGTTGCTTACAATTTTTTTAATTTTGTATTTTCCAAGTGTGCATATTGTACACTTTTTT GGGGATATGCTTAGTAATGCTACGTGTGATTTTTCTGGAGGTTGATAACTTTGCTTGCAGTAGATTTTCTTTAAAAGAATGGGCAGTTAC ATGCATACTTCAAAAGTATTTTCCTGTAAAAAAAAAAAAGTTATATAGGTTTTGTTTGCTATCTTAATTTTGGTTGTATTCTTTGATGTT AACACATTTTGTATAATTGTATCGTATAGCTGTATTGAATCATGTAGTATCAAATATTAGATGTGATTTAATAGTGTTAATCAATTTAAA CCCATTTTAGTCACTTTTTTTTTCCAAAAAAATACTGCCAGATGCTGATGTTCAGTGTAATTTCTTTGCCTGTTCAGTTACAGAAAGTGG TGCTCAGTTGTAGAATGTATTGTACCTTTTAACACCTGATGTGTACATCCCATGTAACAGAAAGGGCAACAATAAAATAGCAATCCTAAA GCAAGAATATGGCAGAACAAGATCTGTAAGCACAGTCTTATTTTCTTTTGTTGTCCAGAATACTTATAATTCTTGAGCCTCCCAGAAATT GGAAGCTAAATAAAGCAACTCAAGTTTCCTTTATTTTGCACTCAATTACAGTGATTATTGATGAAAGCGATGCATGGATATTTTAATACT TCCTACATGTCCTGACTTCTGAAAGAGAGTAGGTAACAGGCATCCCGAGTTCAGGAACTACCTCAGAACACCCCAGGCCAGGTTGGTCAT AGGCTGTGATTTTAGCCCCCGGCAAGTGTGAGTGAAGCATCTGTACCACCGCGCAGGCTGAGCGCCTGCGCAGGGTAAGGTGCCACCTGG CAGTGGGGCACACAGAGGGAAGACCAGGCCTGTCCATCAGCCGGCTGCCTTCAGAGGCAGCTCCAGCAGGACCTTGGCTTGTCTGACAGG AAATGCTTGTGGTCGTTGGTTATTTGGTTTGAGAGCCCTTGTTCCTCCATCTAGTGGAGTCCTTATTAAATGCTAGCAATGTGGCAATTG AGTGCCAGTAGCTTAATTTCATGTTTCTAAATGGACACTGGGTGCAAATCGGCAAGGTGATTAGATTATTAGAAAATTCTGCTCAATGAG TACCTCTCACATTGTAACCTCTTAAATGTACGATTATAATGTTGGATCTTAGGTCAAATAACAGACTTGAGAATACTTTATAAACTGCCA TGATACAGCAAAATCTCATTTATTCAAAGTGCAAACATACTGTGTGTCTTTCTGTTTTGTGTATGCTTGACTGCAAGATAAATGACAAAC TAGCTAATATCCGAGATTTATTTACAAATGGCCAGGGACCCCATCAGGTGAAACACATAGCCCATTGTCTTAGAGCTTCTCCATCGGTCC TGTACAGGAGGATTGGTGACCTACTAACAGTGACCCTGTGGCTCTGTGGAATTTTGAAGTGCCTTTTGTGAATCATGAATGAAACATTTA ACTTGAGACCCTTTAAAAAATTCATCCAGAATCTGTTACCCCTTGGGTAGTTTGATGGAACTGAGTTAAGCAGAAGACCCCAGCTGTTTT CTGGGTAAGCCAGGCTTTGCTGTATCTGGCAGTCAGGAGAGAGGTCAGCCCATGGTGGAGGTCTTCAGTGCCGAGGGCTCGGATGAGAAC GTGTAGTTCTTTGACTTGGACCTGGGCAGCGTCTTCTATGGATGCCTGCCTTGTGAGCACCCACACCTTCCCTCCCCACTGTCGGGTTGA GTAGCCCCAGCGTGGCTGTGTTAGGAGTCCTTTGCCCAACATTGTGCTGCACTGGAGCCTGGCCCTGGCACTGTCCTCAGGACCCTGCCC AAGGGCCCACCGCAGAGCACACCTATGCTATGGGGAGCCCTGCTGGCAGCCCCGAGAGCCATGCCATGGCCTGCAGGAGCCAGGCTCCTG TGTGGATGAAGTCCCTCTTCCTCTGTGCCTTGATCCCTTGGGGGTGCCTTTGGTCATCTCTTCTGTCCTTTCCTGTCTCTGAAATAGTCA TCACTCCCCTTGACTCTCTCTGTTCACGTCTTCTCAGTCTGCAGAGTTAACTTCTGTAAGGAGTTTAATCTGGGGTTCCAAGAAAACAAG TTCCTTGTTAACATAGCACTGACTTTGCAACAATAGAAAACTAACAAATGAGCAACAATATAAAGAGTAGAGGTAGTTCTCATTGGGTGT AACTTCAACCCATTCTGCTTGTGGTTAGAATTTATAATTTTGCTAACGATGTAATTTACTAAGGTTTGAAATGGTATTCTAACAGTGAGT CCATTGTCTTGAGGATTAATCTGATTTATAAGTAATACTGATAGACATATTTTCGTACATCTGAGCAGAAATAAATGCATGTTTCTAGCA TATGTAATATAAAAACTCCAGAGGATAAGTTTACACTTAACAAGATGTTGTTTTCTATTTTTGAATTTCTTATTATTTCCCCCTTTTTGG TAGTGGAGTTGAGAGGGGGAGCATACTATTTGTATAAAGAACTGTCACCCCAGAGTGACATTTATTTTCCAAGATGACCCTGAACTCATG CTGTTGGTTTCATATGGTGTTTGTGTGCTTTGCCTAGATTCAAGGCCTGAGGATTTGAGGAAAATCGGGATTTTTTTTTTCCTATTTGGT TTTCATGTAAAAGTTCTAAATGTCACTTATTTTGCTAAATAAGACCCTTTCACAGGATAGTGTGCGCAATACCTGTCCGTGTTTCCAAGC AGAGTTCAAGTTCATGTCTTCACAAGTAGATGAGAGTCACTTCCAGTCGGGGGAAGCCCGCCTGAGCAGTGTTTTGAGAGTGCGTACATT GGAGGACTGCCCCACGTCCGTTTGCACTCTGCCTTGCAAAACTTACTGTGGAGACGTGTCCCAGACTGGTCTCAGACCAGAGTTTGTGGC ACAGGAAAACCTGGCCCCCTAAAAAGAAGTTTTGGAATTGGAAGCCTGATAATTTCGGGAGGCTGAGGCAGGAGAACGGCGTGAACCCGG GAGGCGGAGCTTGCAGTGAGCCGAGATCGCACCACTGCACTCCAGCCTGGGTGACAGAGCAAGACTCCGTCTCCCAAAAAAAAAAAAAAA AAAAAAAAAAAGGAAACCTGACAATTCTACCCACCTCCCCCCACCCCCGACTATAGGCAAAGAGAGTTGATCACTTCCAGGGTCTCTGAC TTCTGTGACCTGGAAATCAGCCTGGCTTGGGAAATTCATGTTGTTGATCTTTAATTATTTAATTATTCTTTAATAATCCTTCTATTTTCT TGACATCTGACCCCCAGCAAGAGTAAGGATCCCAGAGGTCAAAACAGTGGTGAGAGCCAAGCTGCTCACAGACACCCACTTGATGCCACA GCCATGCCATGAGGCTTCCTCCCAGCTGCTCTGCTGGCTTGCTGAAGCCAGCTCTGAGTCACAGGGTTGCCTTGGACCCTCGGCTGTAGG GGGCACCTGTCTGGCTCCGGGCCCTTTGTCCTGGATACACTGACAGTAATGTGAGCGCAGCACTTCAGAGTTCAGGCCCAGCAGGTCCTG GCAAGTGCATTCCACCCGAACTTTTAACCCAAGCGGTGGGGAAGGAAGCCAAAACTCCAAGCTGCACTTTCTTGGGGTTCTGGCCATGCA CTTCTTAGCCTTCTCTCTGACTTTACAGGACAAAAGGTACCCCACGCCTTCAGAATCATGCTTACCTGCACGGCAGCATCTGACTGGATG GCTGGCTAGGTCTCATCCACCCCAAATTACTGACCCTTGATTTATGTTGTTACTGCTCAGGTTATGCTCAGATGCCCTGGTTGCCTGAAG ATGGTTTAAGTGCAGGCCCTTCAGACAAGTCACGTCAGGCAAGAGAGGGCTGGCCTCTGACCCACAAGAGGGCAGATTTGTGGCCAAGAG GCTTCCTGGCATCCACCCCCAGGCCCAAGGGATCAGTGTGGTGCCAGAGAGGATCTTTAAGCTGGGACTGTACTGAGGCTTGATGGGAAG TATGGGCAGCATGTACTTGACACGTTATCACCCAGTCCCCTTGTAAAATCTGGAATGGAGCGTTTAAGCTGAGCGTTAGCATCAGGTCAG CAGGCAAAGCAAACCTCCCACAAACTGGGTGCCGTAAGGTGGGAGGTGACACATGGAGAGCTTCGTCCTGGCCGAGCAGGCACCCAGCCC CATGTCCCCCGCCAGCATTCTGGATGTCAGAGGAGGGTGCGTGTGATGGCGTCACATTCATCTGAAGCACACTGATTGATTTTCCACAAG GTGGCAAGTTTGATCAAATTGACCGCTTTTCATGAGACACCCAGATGCTGTAAAAAAAAAAAACAGCACTGGGATGTGTTGAGGAGGGGG CAGTTTGCTGTGCTCTGTTCTGTCTGCTGCTCTCTCTGGGGGCCGCACAATGTCCGCACACATCACGGAGGGGAGAAAGGCATCAGTACC AAACGGAACAACCTCTTTTTTCTACATTGTCCATACCCGGACATGTGAGGCTCTATTATCAACAGGTGGTGAGAAAAATTATGTTTTTAT TCGCTTTCTGGTAACTTCTGTAGGCCCTGGCTCAAGGACTTAGCATTTCGTCTCATGTACATCTTTTTCTTAAGTGTTCTTTGCCATTTC TGGAATTGTCCTTGGTTTTTCCTTAGCTCATAGGTCATAGATGCAGAAATATAGTATTTAAGGCATCCGCATCCAGCATCAGATGGCTTT GCATCCAGAAAAACATTGATAACTCAGTTTGAAGCACCAAGCATGTGTAATATGGCTCTATACAATATAATAAATGCATAATGTTAAGCT |
Top |
FusionGenePPI for IGF2_YY1 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
IGF2 | NOV, IGFBP7, IGFBP1, TF, IGFBP3, VTN, IDE, IGFBP6, IGFBP4, IGFBP5, BAG6, NMRK2, FAF1, PCSK4, RBPMS | YY1 | FKBP1A, YAF2, MTA2, NOTCH1, SAP30, HDAC1, HDAC2, HDAC3, KAT2B, EP300, FKBP3, RYBP, SP1, SREBF1, MYC, ATF6, PPIA, CTCF, HDAC4, ATF2, ZNF232, HOXA11, MAX, CREBBP, HDAC5, TP53, MDM2, CDKN2A, SMAD4, SMAD1, SMAD2, SMAD3, PRMT1, ILF3, NPM1, TFAP2A, EZH2, INO80, TFCP2, PRKDC, ACTR8, HSPA4, ACTR5, ACTL6A, RUVBL1, RUVBL2, RELB, YY1, JUNB, JUND, RB1, NFE2L2, MECP2, TERF1, TERF2, INO80C, INO80E, NFRKB, TCF3, INO80B, UCHL5, INO80D, MCRS1, TFPT, HSPA5, BCL6, NEDD4, UHRF2, CREB1, ATF7, BAP1, HCFC1, NEDD4L, XRCC6, XRCC5, SMARCAD1, DDX5, DDX3X, SP3, PSMD9, SKP2, ELAVL1, EED, APP, ZNF830, NHP2L1, ZNF638, NCL, WDHD1, ZNF24, ARRB1, RING1, RNF2, PCGF2, LAMC2, GABPB1, GABPA, SLC39A7, CRKL, GRN, NFKB1, RAF1, TESK1, NR1H2, SPRY1, SHFM1, SMURF2, SUZ12, BMI1, TWIST1, PPP1R3B, TMEM150A, TRPV5, CEP164, BAX, FOXB1, FOXJ2, FOXL1, FOXN1, KMT2E, DNMT3L, AURKA, ID2, F9, TRIM25, AGO2 |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for IGF2_YY1 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for IGF2_YY1 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | IGF2 | C0004903 | Beckwith-Wiedemann Syndrome | 2 | CTD_human |
Hgene | IGF2 | C0015934 | Fetal Growth Retardation | 2 | CTD_human;HPO |
Hgene | IGF2 | C0036341 | Schizophrenia | 2 | PSYGENET |
Hgene | IGF2 | C0206686 | Adrenocortical carcinoma | 2 | CTD_human;HPO |
Hgene | IGF2 | C2239176 | Liver carcinoma | 2 | CTD_human;HPO |
Hgene | IGF2 | C0000786 | Spontaneous abortion | 1 | CTD_human |
Hgene | IGF2 | C0002395 | Alzheimer's Disease | 1 | CTD_human |
Hgene | IGF2 | C0002871 | Anemia | 1 | CTD_human |
Hgene | IGF2 | C0004153 | Atherosclerosis | 1 | CTD_human |
Hgene | IGF2 | C0004352 | Autistic Disorder | 1 | CTD_human |
Hgene | IGF2 | C0005941 | Bone Diseases, Developmental | 1 | CTD_human |
Hgene | IGF2 | C0009241 | Cognition Disorders | 1 | CTD_human |
Hgene | IGF2 | C0009375 | Colonic Neoplasms | 1 | CTD_human |
Hgene | IGF2 | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
Hgene | IGF2 | C0018273 | Growth Disorders | 1 | CTD_human |
Hgene | IGF2 | C0019284 | Diaphragmatic Hernia | 1 | CTD_human |
Hgene | IGF2 | C0020224 | Polyhydramnios | 1 | CTD_human |
Hgene | IGF2 | C0020615 | Hypoglycemia | 1 | CTD_human |
Hgene | IGF2 | C0023903 | Liver neoplasms | 1 | CTD_human |
Hgene | IGF2 | C0025261 | Memory Disorders | 1 | CTD_human |
Hgene | IGF2 | C0027708 | Nephroblastoma | 1 | CTD_human;HPO |
Hgene | IGF2 | C0027746 | Nerve Degeneration | 1 | CTD_human |
Hgene | IGF2 | C0028754 | Obesity | 1 | CTD_human |
Hgene | IGF2 | C0030567 | Parkinson Disease | 1 | CTD_human |
Hgene | IGF2 | C0032045 | Placenta Disorders | 1 | CTD_human |
Hgene | IGF2 | C0032927 | Precancerous Conditions | 1 | CTD_human |
Hgene | IGF2 | C0035412 | Rhabdomyosarcoma | 1 | CTD_human |
Hgene | IGF2 | C0175693 | Russell-Silver syndrome | 1 | CTD_human |
Hgene | IGF2 | C0206624 | Hepatoblastoma | 1 | CTD_human;HPO |
Hgene | IGF2 | C0678807 | prenatal alcohol exposure | 1 | PSYGENET |
Hgene | IGF2 | C0752347 | Lewy Body Disease | 1 | CTD_human |
Tgene | YY1 | C0007873 | Uterine Cervical Neoplasm | 1 | CTD_human |
Tgene | YY1 | C0019693 | HIV Infections | 1 | CTD_human |
Tgene | YY1 | C3714756 | Intellectual Disability | 1 | CTD_human |